Production of immunogenic one-component avian H7-subtype influenza virus-like particles

Process Biochemistry

Volumn 46, Issue 6, 2011, Pages 1292-1298

  Chang, Gary Ro Lin ^a   Lai, Su Yuan ^b   Chang, Poa Chun ^a   Wang, Min Ying ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Hemagglutinin; Influenza virus; Vaccine; Virus like particles

Indexed keywords

AVIAN INFLUENZA; CULTURE SUPERNATANT; GENETIC MATERIALS; HEMAGGLUTININ; INFLUENZA VIRUS; INSECT CELLS; MATRIX; SUBUNIT VACCINE; TRANSMISSION ELECTRON; TWO-COMPONENT; VIRAL CAPSIDS; VIRUS-LIKE PARTICLES;

ANIMALS; CELL CULTURE; TRANSMISSION ELECTRON MICROSCOPY; VACCINES;

VIRUSES;

AVES; GALLUS GALLUS; HEXAPODA; MIRIDAE; ORTHOMYXOVIRIDAE;

EID: 79955636942     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2011.02.019     Document Type: Article

References (42)

1. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis 2006;12:73-7. (Pubitemid 43143539)
2. Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005;352:323-5.
3. Harris A, Cardone G, Winkler DC, Heymann JB, Brecher M, White JM, et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A 2006;103:19123-7. (Pubitemid 350002838)
4. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, Kwong DL, et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 2007;13:147-9.
5. Nagata K, Kawaguchi A, Naito T. Host factors for replication and transcription of the influenza virus genome. Rev Med Virol 2008;18:247-60. (Pubitemid 352018848)
6. Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 2006;12:881-6. (Pubitemid 43848407)
7. Alymova IV, Taylor G, Portner A. Neuraminidase inhibitors as antiviral agents. Curr Drug Targets Infect Disord 2005;5:401-9. (Pubitemid 43008513)
8. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005;79:2814-22.
9. Baigent SJ, McCauley JW. Influenza type A in humans, mammals and birds: determinants of virus virulence, host-range and interspecies transmission. Bioessays 2003;25:657-71. (Pubitemid 36850794)
10. Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin Emerg Drugs 2008;13:21-40. (Pubitemid 351459413)
11. Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998;252:331-42. (Pubitemid 29013415)
12. Prel A, Le Gall-Recule G, Cherbonnel M, Grasland B, Amelot M, Jestin V. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis 2007;51:484-9.
13. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006;193:1223-8.
14. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007;6:381-90. (Pubitemid 46911601)
15. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003;11:438-44. (Pubitemid 37101484)
16. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 2008;4:5-12. (Pubitemid 351785255)
17. Ho J-Y, Lee L-H, Lin Y-C, Tai Y-J, Chang C-K, Chou Y-m, et al. Vaccine development through terminal deletions of an infectious bursal disease virus protein 2 precursor variant. Process Biochem 2010;45:786-93.
18. Lai S-Y, Lee M-S, Chen H-C, Shen P-C, Jinn T-R, Kao S-S, et al. Production and purification of immunogenic virus-like particles formed by the chimeric infectious bursal disease virus structural protein, rVP2H, in insect larvae. Process Biochem 2004;39:571-7. (Pubitemid 38106139)
19. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on viruslike particles. Virus Res 2009.
20. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009;27:530-41.
21. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001;75:6154-65. (Pubitemid 32553146)
22. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza viruslike particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005;23:5751-9.
23. Tao P, Luo M, Zhu D, Qu S, Yang Z, Gao M, et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol 2009;22:273-81.
24. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009;4:e4667.
25. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006;24:2176-85. (Pubitemid 43255161)
26. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007;81:3514-24. (Pubitemid 46456660)
27. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005;18:244-51. (Pubitemid 40586463)
28. Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999;17:2073-80. (Pubitemid 29172380)
29. Kilbourne ED, Pokorny BA, Johansson B, Brett I, Milev Y, Matthews JT. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 2004;189:459-61. (Pubitemid 38210582)
30. Sylte MJ, Hubby B, Suarez DL. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 2007;25:3763-72. (Pubitemid 46591937)
31. Lee MS, Wang MY, Tai YJ, Lai SY. Characterization of particles formed by the precursor protein VPX of infectious bursal disease virus in insect Hi-5 cells: implication on its proteolytic processing. J Virol Methods 2004;121:191-9.
32. Wood JM, Kawaoka Y, Newberry LA, Bordwell E, Webster RG. Standardization of inactivated H5N2 influenza vaccine and efficacy against lethal A/Chicken/Pennsylvania/1370/83 infection. Avian Dis 1985;29:867-72.
33. Ali A, Avalos RT, Ponimaskin E, Nayak DP. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 2000;74:8709-19. (Pubitemid 30666721)
34. Enami M, Enami K. Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein. J Virol 1996;70:6653-7. (Pubitemid 26307370)
35. Zhang J, Pekosz A, Lamb RA. Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins. J Virol 2000;74:4634-44. (Pubitemid 30237888)
36. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 2010;45:226-34.
37. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A. Influenza virus matrix protein is the major driving force in virus budding. J Virol 2000;74:11538-47. (Pubitemid 32222302)
38. Chen BJ, Leser GP, Morita E, Lamb RA. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007;81:7111-23. (Pubitemid 46986647)
39. Jarvis DL, Finn EE. Biochemical analysis of the N-glycosylation pathway in baculovirus-infected lepidopteran insect cells. Virology 1995;212:500-11.
40. Kuroda K, Geyer H, Geyer R, Doerfler W, Klenk HD. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology 1990;174:418-29. (Pubitemid 20060145)
41. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008;82:11813-23.
42. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008;26:3352-61.